euro adhoc: Intercell AG / Financial Figures/Balance Sheet / Intercell announces Q4 and preliminary full-year 2007 results: First profitable year in company history - Vaccine against Japanese Ence

--------------------------------------------------------------------------------
Disclosure announcement transmitted by euro adhoc. The issuer is responsible
for the content of this announcement.
--------------------------------------------------------------------------------

quaterly report

03.03.2008

First profitable year in Intercell´s history - Clear growth in
revenues and profitability expected for 2008

» EUR 5.0 m net profit and positive operating cash flow of EUR 41.7 m
» Revenues of EUR 53.3 m, an increase of 127.5 percent - driven by
payments from strategic alliances » R&D costs of EUR 40.4 m enabled
all programs to be progressed forward at full speed in order to
fully take advantage and create the maximum possible value from the
development programs and technology platforms » Strong cash position
with EUR 287.6 m - plus, unconditional EUR 40.0 m payment already
committed for 2008 » Clear revenue and profit growth expected in 2008
based on the approval of the Japanese Encephalitis vaccine and on
income from product and technology partnerships » Given this result
and strategy, Intercell joined the ranks of the few profitable
biotechnology companies worldwide

Clear strategy to market for the first product - Intercell´s
investigational Japanese Encephalitis vaccine

» Market Authorization Application (MAA) in Europe and Biological
License

Application (BLA) with the US Food and Drug Administration (FDA) submitted
in December 2007, and already excepted
» Licensure application to Australian Therapeutic Goods Administration (TGA)
submitted in February of 2008
» Intercell Biomedical Ltd. (Scotland) received Manufacturer´s License for
commercial manufacturing

» FDA pre-approval inspection of the facilities pre-scheduled for
April of 2008 » Data from pediatric clinical trials in endemic
countries expected within the next weeks » Intercell´s cooperation
with the US Army, geared toward the long-term supply of the
JE-vaccine for the military, is progressing well - contractual
agreement expected latest upon FDA approval

Novartis alliance

» Phase I clinical trial for an improved seasonal Influenza vaccine
formulated with IC31® completed successfully - Intercell´s adjuvant
IC31® demonstrates very good safety and tolerability profile.
Novartis will continue clinical Phase I/II development of IC31®
adjuvanted flu vaccines in 2008 » Joint therapeutic vaccine program
against HCV met primary endpoints in Phase II - data confirms
findings of the interim analysis from Q3 2007 - statistically
significant viral load reduction and excellent safety profile -
further clinical trials in co-development with Novartis to include
IC31® » Cooperation with Novartis is based on a major strategic
partnership that was signed in July of 2007

Hospital acquired-infections

» S. aureus vaccine - Merck & Co., Inc. has initiated Phase II
clinical development by the end of 2007. Intercell expects further
extension of clinical program into additional indications in early
2008 » Pseudomonas vaccine - preparations for start of clinical Phase
II/III trials in 2008 underway » Pre-clinical candidates for
further nosocomial vaccine and antibody product targets including
Klebsiella have been identified

Tuberculosis

» Further clinical trials started at the Department of Infectious
Diseases at the Leiden University Medical Center, Netherlands,
within the new global franchise to fight Tuberculosis »
Tuberculosis vaccine will be further developed in a collaboration
between Sanofi Pasteur and Statens Serum Institut (SSI) including
Intercell´s adjuvant IC31®, strongly supported by the Aeras Global
Tuberculosis Foundation and the EU

Technology platforms: IC31® & AIP®

» Pneumococcus vaccine candidate funded by PATH on course to entering
clinical Phase I trials in 2008 » Developmental programs and
partnerships in the field of vaccines and monoclonal antibodies for
Group B Streptococcus and hospital-acquired infections to be
accelerated » New partnerships for adjuvant IC31® and the definition
of new vaccine candidates from AIP® expected for 2008

Management Board

» The Management Board, with Gerd Zettlmeissl as Chief Executive
Officer, Werner Lanthaler as Chief Financial Officer, and Alexander
von Gabain as Chief Scientific Officer appointed for a further
three-year term. Thomas Lingelbach appointed as new member of the
Management Board as Chief Operating Officer.

EUR in thousands 3 months ended
Dec 31, Dec 31, Year ended

2007 2006 2007 2006

Revenues 40,790 16,970 53,349 23,452

Net profit/(loss) 27,094 5,618 5,009 (16,143)

Net operating cash flow 69,268 10,032 41,686 (7,979)
Cash and marketable securities,

end of period 287,571 94,421 287,571
94,421

For the complete report please see www.intercell.com

end of announcement euro adhoc
--------------------------------------------------------------------------------

ots Originaltext: Intercell AG
Im Internet recherchierbar: http://www.presseportal.de

Further inquiry note:

Lucia Malfent

Head of Corporate Communications

Campus Vienna Biocenter 2, A-1030 Vienna

P: +43-1-20620-303

Mail to: LMalfent@intercell.com

Branche: Biotechnology
ISIN: AT0000612601
WKN: A0D8HW
Börsen: Wiener Börse AG / official market